Keratitis - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 70
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: KAA0067F282EN
Leaflet:

Download PDF Leaflet

Keratitis - Pipeline Review, H2 2016
Keratitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2016, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively for Keratitis.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Keratitis Overview
Therapeutics Development
Pipeline Products for Keratitis - Overview
Pipeline Products for Keratitis - Comparative Analysis
Keratitis - Therapeutics under Development by Companies
Keratitis - Therapeutics under Investigation by Universities/Institutes
Keratitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Keratitis - Products under Development by Companies
Keratitis - Products under Investigation by Universities/Institutes
Keratitis - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corporation
Dompe Farmaceutici S.p.A.
NanoViricides, Inc.
ReceptoPharm, Inc.
RegeneRx Biopharmaceuticals, Inc.
SIFI S.p.A
The Medicines Company
Keratitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acyclovir sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-2088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpecide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIM-45 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polihexanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-259 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPI-MN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Neurotrophic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tigecycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Keratitis - Dormant Projects
Keratitis - Discontinued Products
Keratitis - Product Development Milestones
Featured News & Press Releases
Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease
Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 70

LIST OF TABLES

Number of Products under Development for Keratitis, H2 2016
Number of Products under Development for Keratitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Keratitis - Pipeline by NanoViricides, Inc., H2 2016
Keratitis - Pipeline by ReceptoPharm, Inc., H2 2016
Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
Keratitis - Pipeline by SIFI S.p.A, H2 2016
Keratitis - Pipeline by The Medicines Company, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Keratitis - Dormant Projects, H2 2016
Keratitis - Discontinued Products, H2 2016 61

LIST OF FIGURES

Number of Products under Development for Keratitis, H2 2016
Number of Products under Development for Keratitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Keratitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 83 pages
Immunitor, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 23 pages
Quest PharmaTech Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 33 pages
Spinal Stenosis - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 42 pages

Ask Your Question

Keratitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: